Association of thrombopoietin-related drugs with thromboembolic events: Mendelian randomization and a real-world study
C Liang, Q Chen, Y Zhang - Therapeutic Advances in Drug …, 2024 - journals.sagepub.com
Background: Studies have shown conflicting results when using thrombopoietin-related
drugs (TPORD) for thromboembolic events (TEEs). Our study aimed to explore the …
drugs (TPORD) for thromboembolic events (TEEs). Our study aimed to explore the …
The impact of thrombopoietin on clinical practice
R Basser - Current pharmaceutical design, 2002 - ingentaconnect.com
Prevention of hemorrhage secondary to thrombocytopenia has generally been managed by
the transfusion of platelets. The need for such transfusion is related to the depth and …
the transfusion of platelets. The need for such transfusion is related to the depth and …
Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized …
F Catalá-López, I Corrales… - … Clínica (English Edition), 2015 - Elsevier
Background and objective Romiplostim and eltrombopag are thrombopoietin receptor
(TPOr) agonists that promote megakaryocyte differentiation, proliferation and platelet …
(TPOr) agonists that promote megakaryocyte differentiation, proliferation and platelet …
Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized …
F Catala-Lopez, I Corrales, G Martín-Serrano, A Tobías… - Medicina Clínica, 2012 - Elsevier
BACKGROUND AND OBJECTIVE: Thrombopoietin receptor (TPOr) agonists (romiplostim
and eltrombopag) are a new approach for the treatment of thrombocytopenia-associated …
and eltrombopag) are a new approach for the treatment of thrombocytopenia-associated …
Thrombopoietin: an update on therapeutic potential
CR Underhill, RL Basser - BioDrugs, 1999 - Springer
Thrombopoietin (TPO), the central regulator of megakaryocytopoiesis, was first identified in
1994 and since then much has been learnt about megakaryocyte and platelet physiology …
1994 and since then much has been learnt about megakaryocyte and platelet physiology …
[HTML][HTML] PCV5 Thromboembolisms with Thrombopoietin Receptor Agonists: Systematic Review and Meta-Analysis of Randomized Controlled Trials
I Corrales-Álvarez, F Catalá-López… - Value in …, 2011 - valueinhealthjournal.com
Objectives Romiplostim and eltrombopag are thrombopoietin receptor (TPOr) agonists that
promote megakaryocyte differentiation, proliferation and platelet production. Both are …
promote megakaryocyte differentiation, proliferation and platelet production. Both are …
[HTML][HTML] Thrombopoietin receptor agonists: ten years later
The two thrombopoietin receptor agonists (TPO-RA), eltrombopag and romiplostim, were
licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then …
licensed in the US for treatment of immune thrombocytopenia (ITP) in 2008 and, since then …
[HTML][HTML] Knowledge map of thrombopoietin receptor agonists: A bibliometric analysis
R Hu, S Guo, M Liu - Heliyon, 2024 - cell.com
Background Thrombopoietin receptor agonists (TPO-RAs) have been widely used to treat
thrombocytopenia, however, a scientometric profile of TPO-RAs research is lacking …
thrombocytopenia, however, a scientometric profile of TPO-RAs research is lacking …
[HTML][HTML] Comparative efficacy and safety of thrombopoietin receptor agonists in adults with thrombocytopenia: a systematic review and network meta-analysis of …
J Deng, H Hu, F Huang, C Huang, Q Huang… - Frontiers in …, 2021 - frontiersin.org
Thrombopoietin receptor agonists (TPO-RAs) play a crucial role in stimulating
thrombopoiesis. However, conventional meta-analyses have shown inconsistent results …
thrombopoiesis. However, conventional meta-analyses have shown inconsistent results …
Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®
TTL Nguyen, A Palmaro, F Montastruc… - Drug safety, 2015 - Springer
Introduction Eltrombopag and romiplostim are thrombopoietin receptor agonists (TPO-RAs)
marketed for immune thrombocytopenia (ITP). Thrombotic events have been reported with …
marketed for immune thrombocytopenia (ITP). Thrombotic events have been reported with …